Navigation Links
Phosphagenics Announces Positive Proof of Concept Results from,Studies Utilizing Company's Dermal Drug Delivery Technology

MELBOURNE, Australia, June 25, 2007 /PRNewswire-FirstCall/ -- Phosphagenics Limited (AIM: PSG) announced today positive results from pre-clinical studies of its TPM-02 dermal drug delivery technology formulated with retinoic acid, a leading topical treatment for severe acne and an active ingredient used in anti-aging cosmetics.

The proof of concept studies showed a three-fold increase in the amount of retinoic acid delivered into the skin when formulated with TPM-02 compared to a control formulation. Importantly, there was no retinoic acid detected in the bloodstream. TPM-02's ability to deliver an active ingredient to the dermis, the active layer of the skin, highlights the system's potential use in dermatologic and cosmetic products.

This study builds upon Phosphagenics' successes in delivering drugs, including insulin, through the skin without causing skin irritation, and further demonstrates that the TPM-02 technology can be utilized to deliver and hold an active ingredient in the skin, which is optimal in achieving maximum effectiveness from dermatological and cosmetic products.

"These proof of concept studies demonstrate the adaptability and flexibility of Phosphagenics' delivery technology, and we intend to leverage these results in pursuing opportunities in the dermatological and cosmetic fields," said Dr. Esra Ogru, Executive Vice President R&D at Phosphagenics. "The ability to deliver greater amounts of retinoic acid to the skin will produce more effective products for consumers, which is our objective in the areas of dermatology and cosmetics."

In addition to improving the dermal delivery of retinoic acid, Phosphagenics sees broader applications for its TPM-02 technology with additional pre-clinical studies showing potential in the dermal delivery of other compounds, such as coenzyme Q10 (CoQ10) and omega-3 fatty acids.

About Phosphagenics Limited

Phospha genics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products. The Company's core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutraceuticals, as well as to assist in the production of drug delivery platforms. Phosphagenics' shares are listed on the Australian Stock Exchange (POH) and the London Stock Exchange's Alternative Investment Market (PSG). An ADR -- Level 1 program has been established in the US with the Bank of New York (PPGNY) for US investors to trade in Phosphagenics' stock on the "over-the-counter" market.

For more information, please visit Phosphagenics' web site at http://www.phosphagenics.com

CONTACT: Company, Dr. Esra Ogru, Executive Vice President Research &Development, +1-646-706-2155, or Harry Rosen, President and CEO,+1-646-715-3581, both of Phosphagenics Limited; or U.S. Investors andMedia, Brian Ritchie or Evan Smith, of FD, +1-212-850-5600, forPhosphagenics Limited

Web site: http://www.phosphagenics.com/

Ticker Symbol: (NASDAQ-OTCBB:PPGNY)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
Breaking Medicine News(10 mins):